Moffitt requests support (10.8 calendar months, FTE, $225,849) for an experienced leadership team that includes: ? William S. Dalton, PhD, MD, Center Director ? W. Jack Pledger, PhD, Deputy Center Director and Associate Center Director for Basic Sciences ? Thomas Sellers, PhD, Associate Center Director for Cancer Prevention and Control ? Daniel Sullivan, MD, Associate Center Director for Clinical Investigations ? James Mule, PhD, Associate Center Director for Translational Research In addition, the Senior Leadership description and request for the Vice President for Research, Michael Benedict, PhD, is included in the Administration section. Responsibility and final authority for all scientific, clinical and operational decisions reside with the Center Director, Dr. William Dalton, who is the Chief Executive Officer of the organization. Reporting directly to the Center Director are four Executive Vice Presidents/Associate Center Directors (ACDs), who are responsible for coordinating research activities of the Center along with a Vice President for Research. The Center Director and senior leaders interact frequently including weekly meetings. The Associate Center Directors and Vice President of Research meet weekly as the Research Executive Committee to discuss research related issues. Clearly defined roles for both leadership and the advisory bodies contribute to Moffitt's ability to move quickly and strategically to meet its goals. Over the last five years, two changes relevant to the CCSG senior leadership occurred: ? In 2007, Michael Benedict, PharmD was recruited as Vice President of Clinical Investigations. With the retirement of Anne Goff in 2009, Dr. Benedict was appointed the sole Vice President of Research. ? James Mule, PhD's senior leadership role as Executive Vice President has evolved and he now serves as EVP and Associate Center Director of Translational Research. He replaces Timothy Yeatman, MD, whose leadership role shifted to another area of the Cancer Center.
The Senior Leaders oversee the Center's overall operations of research including strategic planning, recruitment, CCSG oversight, translational and collaborative efforts, the interface between research and clinical activities, and the implementation of policy.
|Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612|
|Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53|
|Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303|
|Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73|
|Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :|
|Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :|
|Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029|
|Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :|
|Schabath, M B; Welsh, E A; Fulp, W J et al. (2016) Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35:3209-16|
Showing the most recent 10 out of 974 publications